Condition: Cryptococcal Meningitis · Sponsor: Makerere University
This will be a randomized controlled trial of asymptomatic (Cryptococcal Antigen test)CrAg positive persons in Uganda. Patients will be randomized to receive preemptive treatment with 1 dose of liposomal amphotericin (10mg/kg) in addition to standard of care fluconazole therapy. How the enhanced antifungal therapy prevents progression to meningitis in the first 24-weeks and overall survival in those who receive the intervention compared with participants receiving fluconazole per World Health Organisation (WHO) and national standard of care therapy will be evaluated.
This description comes directly from the study's public registry record.
DAVID MEYA, PhD · +256 772 543 730 · david.meya@gmail.com
ELIZABETH NALINTYA, MPH · +256 771 321 617 · enalintya@idi.co.ug
Always discuss trial participation with your own doctor first.
| infectious Disease Institute Kampala,Uganda | Kampala, Uganda | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03945448